Liquidia to Present at the 2020 Jefferies Virtual London Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia Technologies (Nasdaq: LQDA) announced that CEO Neal Fowler will present at the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020, at 7:55 PM GMT. The presentation will be available via a live audio webcast, with a replay accessible for at least 90 days. Liquidia is focused on developing innovative products using its proprietary PRINT® technology, particularly two candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain relief.
Details
News Market Reaction – LQDA
The recorded move for LQDA in the trading session of this news was -13.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present at the 2020 Jefferies Virtual London Healthcare Conference at 7:55 PM GMT (2:55 PM ET) on Thursday, November 19, 2020.
A link to the live audio webcast and replay of the presentation will be available on the Events & Presentations page of the Company’s corporate website, and will be archived for a minimum of 90 days.
About Liquidia
Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.
Contact Information
Investor Relations:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.